NYC’s Leading Integrative Health Care Center
NYC’s Leading Integrative Health Care Center
Hepatitis C is a bloodborne viral infection that quietly inflames the liver for years, often with no symptoms at all, until fibrosis, cirrhosis, or a routine blood test finally brings it to light. At Patients Medical, our NYC physicians pair the curative antiviral medications that clear HCV with functional testing that identifies and repairs the metabolic, digestive, and inflammatory damage the virus leaves behind.
Americans currently living with HCV
Cure rate with modern antiviral therapy
Of infected people unaware of their status
Typical antiviral treatment course
Board-certified integrative medicine physician.
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV), transmitted through contact with infected blood, that can remain asymptomatic for 10 to 20 years while progressively scarring the liver. It is diagnosed through HCV antibody and RNA blood testing and is curable in more than 90 percent of cases with 8 to 12 weeks of direct-acting antiviral medication.
Hepatitis C is an infection of the liver caused by the hepatitis C virus, a small RNA virus that enters the bloodstream and specifically targets hepatocytes, the liver’s primary functional cells. Once inside a hepatocyte, HCV hijacks the cell’s machinery to replicate, triggering an immune response that inflames liver tissue in the process of trying, often unsuccessfully, to clear the virus on its own.
In roughly 15 to 25 percent of people, the immune system clears HCV spontaneously within six months of exposure, a pattern called acute self-limited infection. In the remaining 75 to 85 percent, the virus evades clearance and establishes chronic infection, in which repeated cycles of hepatocyte injury and immune-mediated inflammation slowly activate hepatic stellate cells to lay down collagen. Over years, this fibrotic process can progress to cirrhosis, portal hypertension, and, in a subset of patients, hepatocellular carcinoma.
Conventional hepatology treats hepatitis C purely as a virological problem to be eliminated with antivirals, which is correct as far as it goes. Functional medicine adds a second layer: even after the virus is undetectable, many patients are left with disrupted gut-liver axis signaling, depleted glutathione reserves, altered lipid metabolism, and lingering inflammatory markers that standard post-treatment care rarely addresses. We do not dispute the antiviral cure; we build on it.
HCV affects an estimated 2.4 to 3.5 million people in the United States, with the highest new-infection rates currently occurring among adults aged 20 to 39, largely linked to the ongoing opioid epidemic and injection drug use. Roughly half of people living with HCV are unaware of their infection, which is why the CDC now recommends universal one-time screening for all adults.
The liver’s primary metabolic cells, and HCV’s direct target. Chronic infection triggers repeated hepatocyte injury and regeneration cycles that drive fibrosis over time.
Normally dormant, these cells activate in response to chronic inflammation and begin producing collagen, the structural basis of liver fibrosis and eventual cirrhosis.
The liver receives roughly 70 percent of its blood supply from the gut via the portal vein. Chronic HCV infection is associated with increased intestinal permeability, compounding hepatic inflammation.
Because hepatitis C causes gradual, low-grade liver inflammation rather than an acute illness, its symptoms are often vague, intermittent, and easy to dismiss for years before a diagnosis is made.
Driven by cytokine release and impaired hepatic glycogen storage.
Reflects ongoing immune activation against the virus.
Linked to appetite suppression and altered metabolism.
From circulating inflammatory cytokines.
Tied to reduced hepatic energy output.
Associated with low-grade hepatic encephalopathy even before cirrhosis.
Linked to circulating ammonia and inflammatory markers.
HCV can cross the blood-brain barrier and affect neurotransmitter signaling.
Tied to disrupted melatonin clearance by the liver.
Often compounded by chronic fatigue.
From hepatic capsule stretching as inflammation progresses.
Related to impaired bile production.
Yellowing of skin/eyes from impaired bilirubin clearance, typically a later-stage sign.
Reflects bilirubin metabolism disruption.
Linked to portal pressure changes and gut-liver axis disruption.
From impaired hepatic clotting-factor production.
Small dilated blood vessels linked to elevated estrogen clearance deficits.
From bile-salt accumulation under the skin.
Linked to circulating immune complexes.
A later-stage sign of portal hypertension.
Staging matters because it determines urgency, monitoring frequency, and how aggressively post-cure liver support should be pursued. Fibrosis stage is typically assessed with FibroScan (transient elastography) and expressed on the METAVIR F0–F4 scale.
No or minimal scarring detected on imaging. Liver enzymes may be normal or mildly elevated. Most newly diagnosed patients fall into this stage, especially those caught through routine screening.
Fibrous bands are visible on elastography but liver architecture remains largely intact. Patients often have years of undiagnosed infection behind them and may report fatigue or mild digestive symptoms.
Bridging fibrosis connects portal areas, significantly raising the priority for prompt antiviral treatment. Some patients begin to show early portal hypertension signs, such as mild splenomegaly.
Extensive scarring has replaced normal liver architecture. Patients require lifelong hepatocellular carcinoma surveillance even after achieving viral cure, alongside aggressive functional support for remaining liver capacity.
Hepatitis C has one direct cause exposure to HCV-infected blood but the routes of exposure and the factors that influence disease progression are varied and often interacting.
The leading cause of new HCV infections in the U.S. today, accounting for the majority of cases in adults under 40.
Blood supply screening for HCV began in 1992; transfusions or organ transplants before that date carry meaningful exposure risk.
Reused needles or ink pots not properly sterilized between clients can transmit HCV.
Healthcare workers face an estimated 1.8% infection risk per needle-stick exposure to HCV-positive blood.
Shared equipment and vascular access points raise exposure risk in dialysis settings, particularly in older facilities.
Occurs in an estimated 6–7% of infants born to HCV-positive mothers, primarily during delivery.
Shared straws or bills used for insufflation can transmit HCV via microscopic nasal bleeding.
Injections, dental work, or minor surgery performed with reused equipment in under-resourced settings carry elevated risk.
Higher rates of injection drug use and limited access to sterile equipment in correctional settings raise cumulative exposure risk.
Shared transmission routes mean HIV-positive individuals have a substantially elevated likelihood of HCV coinfection.
Uncommon but possible, particularly with practices involving mucosal trauma or in the context of other STIs.
Razors or toothbrushes that carry microscopic blood residue represent a low but real household transmission route.
Several liver conditions share overlapping symptoms with hepatitis C, which is why accurate lab-based differentiation, not symptoms alone, is essential before building a treatment plan.
| Feature | Hepatitis C | Hepatitis B | NAFLD / MASLD | Autoimmune Hepatitis |
|---|---|---|---|---|
| Key biomarker | HCV RNA (viral load) | HBsAg / HBV DNA | Elevated ALT with hepatic steatosis on imaging | ANA, anti-smooth muscle antibody, elevated IgG |
| Best diagnostic test | HCV antibody + RNA PCR | HBsAg + HBV DNA PCR | Liver ultrasound / FibroScan + metabolic panel | Liver biopsy + autoantibody panel |
| Hallmark symptom | Often asymptomatic; fatigue when present | Fatigue, may have acute flu-like onset | Fatigue, right-upper-quadrant discomfort | Fatigue, joint pain, jaundice flares |
| Standard blood test detection | Not on routine panel; requires specific order | Not on routine panel; requires specific order | May show elevated ALT/AST on routine panel | May show elevated ALT/AST; needs specific antibodies |
| Treatment approach | Curative direct-acting antivirals (8–12 wks) | Lifelong antiviral suppression (rarely curative) | Weight management, metabolic correction | Immunosuppressive therapy (steroids, azathioprine) |
| Overlap with HCV | — | Can coinfect via shared transmission routes | HCV directly promotes hepatic steatosis | HCV can trigger autoantibody production |
The most clinically important overlap is between hepatitis C and fatty liver disease: HCV directly interferes with lipid metabolism in hepatocytes, so many chronically infected patients develop steatosis independent of body weight. Learn more on our non-alcoholic fatty liver disease page.
The standard first-line screening test, detecting whether your immune system has ever produced antibodies against HCV. A positive result means past or present exposure, not necessarily active infection — it always requires RNA confirmation.
Confirms whether the virus is actively replicating in your bloodstream right now. This is the definitive test for active infection and the one repeated at week 12 post-treatment to confirm cure (SVR12).
Identifies which of the six major HCV genotypes you carry, which determines which direct-acting antiviral combination your physician will prescribe and for how long.
Measures ALT, AST, bilirubin, albumin, and clotting factors to assess how much functional liver capacity remains and to track improvement through treatment.
A non-invasive ultrasound-based test that measures liver stiffness to stage fibrosis (METAVIR F0–F4) without requiring a biopsy — something standard blood work cannot reveal.
Check all that apply to your current experience:
Curing hepatitis C starts with direct-acting antiviral medication — that is the non-negotiable, evidence-based foundation of every treatment plan we build. Around that foundation, we layer functional medicine support personalized to your fibrosis stage, metabolic labs, and gut health to help your liver recover fully, not just clear the virus.
An 8-to-12-week oral regimen that clears HCV in over 90 percent of patients, selected and dosed based on your genotype and fibrosis stage.
Serial FibroScan and hepatic panels tracked before, during, and after antiviral therapy to document liver recovery and catch complications early.
Targeted nutraceuticals selected to support hepatocyte membrane repair and antioxidant capacity once antiviral treatment is underway or complete.
Stool and organic acid testing guide targeted probiotic strains and gut-barrier support to reduce the endotoxin load reaching an already-stressed liver.
Because HCV directly disrupts insulin signaling, we monitor fasting insulin and HbA1c throughout treatment and correct insulin resistance to reduce steatosis risk.
After SVR12 confirms cure, we continue elastography and lab monitoring at defined intervals to document fibrosis regression and adjust support protocols.
| Weeks 1–12 | Direct-acting antiviral course, with liver panels checked at baseline, mid-treatment, and end of treatment. |
| Week 24 (12 weeks post-treatment) | HCV RNA retested to confirm SVR12, our definition of cure. |
| Months 3–6 | Liver enzymes typically normalize; functional protocols address residual fatigue, gut symptoms, and inflammatory markers. |
| Months 12–24 | Fibrosis regression is reassessed via FibroScan; patients with prior advanced fibrosis continue periodic hepatocellular carcinoma surveillance indefinitely. |
Alcohol is independently hepatotoxic and accelerates fibrosis progression when combined with active HCV infection. Even moderate drinking measurably raises the risk of cirrhosis in HCV-positive patients, so complete abstinence — not just moderation — is the standard we recommend through treatment and for at least 12 months after confirmed cure.
Skeletal muscle is a major site of glucose disposal, and preserving muscle mass improves the insulin resistance that HCV worsens. Start with 20-minute bodyweight or resistance-band sessions three times a week, progressing load gradually as fatigue improves post-treatment.
The liver performs the bulk of its detoxification and glycogen-regulation work overnight. Consistent sleep timing supports hepatic circadian rhythm and has been associated with better liver enzyme trends during antiviral treatment.
Chronic stress elevates cortisol, which worsens insulin resistance and inflammatory signaling already disrupted by HCV. Ten minutes of slow diaphragmatic breathing (4 seconds in, 7 seconds hold, 8 seconds out) once daily measurably lowers circulating cortisol within a few weeks of consistent practice.
Aim for half your body weight in ounces of water daily to support the kidneys and liver in clearing metabolic byproducts of both the infection and, if applicable, antiviral medication metabolism.
Coinfection with either hepatitis A or B substantially worsens outcomes in someone with active or prior HCV infection. If you are not already immune, hepatitis A and B vaccination is a standard, evidence-based step we coordinate as part of your care plan.
Diet cannot cure hepatitis C, but it directly affects two things the virus already stresses: hepatic fat accumulation and systemic inflammation. Because HCV independently promotes steatosis and insulin resistance, dietary choices meaningfully influence how much additional metabolic burden your liver carries during and after antiviral treatment.
Eliminate alcohol and added sugar completely both directly increase hepatic fat deposition and inflammatory load on a liver already managing active viral injury.
These conditions frequently overlap with, complicate, or get confused with hepatitis C, and are commonly assessed together during a full liver work-up.
HCV directly promotes hepatic fat accumulation, so many chronically infected patients develop steatosis independent of body weight or diet alone.
Shares transmission routes with HCV; coinfection is common and changes both monitoring frequency and treatment sequencing.
HCV interferes with insulin signaling directly in liver cells, making glycemic monitoring a standard part of hepatitis C care.
The end-stage consequence of untreated chronic HCV infection in 15–30% of cases, requiring lifelong cancer surveillance even after viral cure.
Persistent fatigue is one of the most common HCV symptoms and can linger for months even after the virus is cleared.
Chronic HCV infection is associated with gut barrier disruption, compounding systemic inflammation beyond the liver itself.
Because hepatitis C so often causes no symptoms until significant liver damage has occurred, don’t wait for symptoms to appear before getting tested — risk factors alone are reason enough to screen.
🚨 Seek emergency medical evaluation immediately if you experience:
Patient experiences shared with permission. Names and identifying details have been altered for privacy; results vary by individual.
Yes. Hepatitis C is a well-defined, universally recognized viral infection caused by the hepatitis C virus (HCV), confirmed by blood testing that detects antibodies or the virus’s genetic material (RNA) directly. Unlike some functional medicine diagnoses that remain debated in conventional circles, hepatitis C has clear diagnostic criteria, an ICD-10 billing code, and, since direct-acting antivirals (DAAs) arrived in 2013–2014, a cure rate exceeding 90–95 percent with an 8-to-12-week oral medication course. At Patients Medical, we treat the antiviral cure as the non-negotiable foundation of care. What functional medicine adds is everything the antiviral prescription does not address: residual liver inflammation, gut and metabolic disruption, and nutrient depletion that can persist after the virus is undetectable. We use functional testing and root-cause protocols to support full liver recovery, not to replace antiviral treatment.
Antiviral treatment itself typically runs 8 to 12 weeks, depending on your HCV genotype, prior treatment history, and whether cirrhosis is present. Cure is confirmed by an undetectable viral load 12 weeks after finishing medication — a benchmark called sustained virologic response (SVR12). Reaching SVR12 doesn’t mean full recovery, though. Liver enzymes typically normalize within 3 to 6 months of clearing the virus, but existing fibrosis can take 1 to 2 years to meaningfully regress, and some patients report lingering fatigue, brain fog, or digestive symptoms for several months after cure. At Patients Medical, we typically see patients move through three phases: antiviral clearance (8–12 weeks), inflammatory resolution (3–6 months), and structural liver recovery (12–24 months), with functional medicine support layered across all three.
Diagnosis starts with an HCV antibody test, which tells you whether you’ve ever been exposed to the virus. A positive antibody result must always be followed by an HCV RNA PCR test, which detects active viral genetic material and confirms whether infection is current. Antibodies can remain positive for life even after a past infection cleared on its own or was cured, so RNA testing is the only way to confirm active infection. If RNA is detected, your physician will typically order HCV genotype testing, since genotype affects which antiviral regimen is prescribed, along with a comprehensive hepatic function panel and, often, a FibroScan to assess existing liver scarring. At Patients Medical we add micronutrient and inflammatory markers to this standard workup so treatment addresses the whole metabolic picture, not just the viral load.
Hepatitis C is more commonly associated with unintentional weight loss and appetite suppression during active infection, but the relationship with metabolism is more complex than that. HCV directly interferes with insulin signaling in liver cells, and chronic infection is strongly associated with insulin resistance and increased type 2 diabetes risk, independent of body weight. Many patients also develop hepatic steatosis — fat accumulation within liver cells — driven partly by the virus itself and partly by the metabolic disruption it causes. After antiviral cure, some patients notice weight changes as appetite normalizes and insulin sensitivity shifts, which is one reason we monitor fasting insulin, HbA1c, and lipid panels throughout treatment, not just before and after.
Hepatitis B and hepatitis C are caused by two entirely different viruses with different transmission patterns, natural histories, and treatments. Hepatitis B (HBV) is a DNA virus preventable with a vaccine; it can be managed with antiviral suppression but is rarely cured outright since it can integrate into liver cell DNA. Hepatitis C (HCV) is an RNA virus with no vaccine available, but it’s curable in the large majority of cases with 8–12 weeks of direct-acting antivirals. Both spread primarily through contact with infected blood, though hepatitis B also spreads more readily through sexual contact and mother-to-newborn transmission. Someone can be infected with both at once, so we test for both when either is suspected, since coinfection changes treatment sequencing and monitoring.
Left untreated, chronic HCV infection drives ongoing low-grade liver inflammation as the immune system repeatedly attempts, and fails, to clear the virus. Over years to decades, this inflammatory cycle triggers hepatic stellate cells to lay down scar tissue (fibrosis), which can progress to cirrhosis in an estimated 15–30 percent of untreated patients within 20 years. Cirrhosis impairs the liver’s ability to filter toxins, produce clotting factors, and regulate metabolism, and raises the risk of liver cancer and liver failure. Chronic HCV infection is also linked to altered gut microbiome composition and increased intestinal permeability, which can perpetuate systemic inflammation outside the liver. This is why our protocols pair antiviral cure with gut-barrier and microbiome support rather than treating the liver in isolation.
The only treatment that clears the hepatitis C virus itself is a course of direct-acting antivirals such as sofosbuvir/velpatasvir or glecaprevir/pibrentasvir, prescribed and monitored by a physician. No supplement, diet, or lifestyle protocol substitutes for antiviral therapy. Once the virus is cleared, or alongside antiviral treatment when appropriate, functional medicine support commonly includes milk thistle (silymarin) for hepatocyte protection, N-acetylcysteine (NAC) to support glutathione production, phosphatidylcholine for hepatocyte membrane repair, and targeted probiotic strains for gut-liver axis support. We individualize these based on lab findings rather than a generic liver-cleanse stack, and always coordinate supplement timing with your antiviral regimen to avoid interactions.
Patients Medical pairs the curative power of modern antiviral medicine with functional testing and root-cause support, so you leave treatment not just virus-free, but with a liver and a body genuinely on the mend.
Antibody, RNA, genotype, and full hepatic function panels in one visit.
Board-certified physicians who explain your results and options in plain language.
Serial labs and FibroScan monitoring so you can see your liver healing, stage by stage.
Call us at (212) 794-8800 · 800 Second Avenue, Suite 900, New York, NY 10017
Patients Medical specializes in gently helping the patient identify the root cause of their medical issues and then assist them to recover from their problems to help them move forward to good health.
To schedule an in person on Tele-medicine appointment, please call our office at (212) 794-8800 or email us at info@PatientsMedical.com We look forward to hearing from you
Patients Medical PC
1148 Fifth Avenue, Suite 1B New York, NY 10128
Copyright © 2026 Patients Medical. All Rights Reserved.
All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice. Statements made on this website have not been evaluated by the Food and Drug Administration. The information contained herein is not intended to diagnose, treat, cure or prevent any disease. Patients Medical.
This website may convey general information related to medical conditions, their research, testing, and treatment, and other health care topics. Any such information is provided for informational purposes only. You should always consult with a doctor or other health care professional for medical advice or information about diagnosis and treatment.
